Could Goldman Sachs Report Be Exposing Pharma’s Real End Game?

By the World Mercury Project Team, via Natural Blaze

Together, the U.S. government and American families are spending billions on medications, therapy, insurance, education, housing, etc. to address the epidemics of chronic childhood diseases. These include autism, ADHD, diabetes, juvenile rheumatoid arthritis, cancer, allergies (including deadly peanut allergies), autoimmune conditions, obesity and more. The costs are staggering.

recent government survey found that 1 in 45 children ages 3 through 17 have been diagnosed with an autism spectrum disorder (ASD). The estimated average lifetime cost to care for a child with autism is $1.4 million if they do not have intellectual disability. An estimated 1 in 5 persons with autism also has intellectual disability. This increases the average lifetime cost of care to $2.3 million.

WMP is calling for a new paradigm that tries to stop the rise of chronic disease and cure those who are suffering now. Since these epidemics are occurring in children, the long-term consequences of so many sick children could be dire for our nation and economy in the future.

The rise in chronic illness in children is coterminous with the vaccine schedule. In 1986, there were 11 vaccines and 12.8% of our nation’s children had a chronic illness. In 2017, there were 54 vaccines—and 2011 figures report an astonishing 54% of children suffer from chronic illness or developmental disability—many of which have been associated with vaccine injuries. WMP believes the U.S. plan must be to do everything possible now to prevent chronic diseases in children and it should start with investigating our broken vaccine program.

“…cures could be bad for business in the long run.”

“Is curing patients a sustainable business model?”

On April 10th, Goldman Sachs (GS) released a report called “The Genome Revolution.” In it, GS asked, “Is curing patients a sustainable business model?” People with chronic illnesses and those who have loved ones suffering with ongoing conditions will find the GS comments repugnant. Both childhood epidemics and opioid addiction are at record highs. Partner those facts with the notion that “one shot and done vaccines” are a thing of the past as today’s failing vaccines require more boosters and it begs the question, Could the Goldman Sachs report be exposing pharma’s real end game of drug dependency vs. curing disease?

The following is an excerpt from a new CNBC investing report:

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run. “Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.

“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”

CNBC reported that GS analysts didn’t immediately respond to a request for comment.

The World Mercury Project is addressing the chronic health issues plaguing our children by educating our communities, leaders and federal agencies to bring about meaningful change on the most important issue of our lifetime—the health and well-being of our children. Everyone—children, parents and family, education leaders and teachers, health care and insurance providers, businesses (like Goldman Sachs and pharmaceutical companies) that employ graduates, our country’s military and more—has a stake in this fight to restore our children’s health. As children are the keys to our successful future and prosperity, we don’t have a moment, or the health of any child, to lose.

Sign up for free news and updates from Robert F. Kennedy, Jr. and the World Mercury Project. Your donation will help to support us in our efforts.
Advertisements

2 thoughts on “Could Goldman Sachs Report Be Exposing Pharma’s Real End Game?”

Share your thoughts

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s